Zi Chen

发表

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy.

T. McDonnell, H. Kantarjian, J. Cortes, 2017, Blood advances.

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.

H. Kantarjian, J. Cortes, Joseph A. DiGiuseppe, 2016, Blood.

Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP).

W. Feng, Xiao-ping Xu, Zi Chen, 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms

S. Verstovsek, L. Medeiros, Z. Hu, 2017, Modern Pathology.

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Dajun Yang, Ya-Zhen Qin, Q. Jiang, 2022, Journal of Hematology & Oncology.

Imatinib Is Cost-Effective Comparing to Interferon-(IFN) for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Healthcare System Perspective.

W. Feng, Zi Chen, Chun Wang, 2007 .

Imatinib Versus Interferon-alpha (IFN) for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Healthcare System Perspective: 12 Months Cost and Cost Per Responder Analyses.

W. Feng, Zi Chen, Chun Wang, 2007 .

Erratum to: Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

L. Medeiros, Z. Gong, G. Tang, 2017, Annals of Hematology.

Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

L. Jeffrey Medeiros, Z. Gong, G. Tang, 2016, Annals of Hematology.

Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients

K. Young, L. Medeiros, Shaoying Li, 2017, The American journal of surgical pathology.

Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases

G. Tang, Wei Wang, Shimin Hu, 2015, American journal of hematology.

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Dajun Yang, Q. Jiang, Y. Zhai, 2020 .

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Dajun Yang, Q. Jiang, Y. Zhai, 2022, Journal of Hematology & Oncology.

A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China

Dajun Yang, Q. Jiang, Xiao-jun Huang, 2022, Blood.

Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

E. Jabbour, Dajun Yang, Y. Zhai, 2022, Blood.

An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia

Dajun Yang, Q. Jiang, Xiao-jun Huang, 2019, Blood.

Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST).

Dajun Yang, K. Tao, Y. Zhai, 2022, Journal of Clinical Oncology.

Extramedullary blast crisis as initial presentation in chronic myeloid leukemia with the e1a2 BCR-ABL1 transcript: A case report.

K. Patel, Wei Liu, Zi Chen, 2015, Molecular and clinical oncology.

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Dajun Yang, Y. Zhai, Yongping Song, 2022, Journal of Hematology & Oncology.

Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

H. Kantarjian, E. Jabbour, Dajun Yang, 2023, Blood.

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Dajun Yang, Y. Zhai, Q. Niu, 2023, Blood.

Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)

T. Kadia, Dajun Yang, Y. Zhai, 2022, Blood.